3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
6
Active not recruiting
4
Unknown
2
Not yet recruiting
2
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
2
Neoplasm Metastasis
1
MMR-D/MSI-H Colorectal Cancers
1
Gestational Trophoblastic Disease
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Interventions
pembrolizumab
3
NVP-BKM120
2
Bevacizumab
2
trastuzumab duocarmazine
1
talazoparib
1
sitravatinib
1
ponatinib
1
niraparib
1
mirvetuximab soravtansine
1
lenvatinib
1
dostarlimab
1
dactolisib
1
bemarituzumab
1
Trastuzumab
1
Taxes
1
TAS-116
1
Sevoflurane
1
Radiotherapy
1
Propofol
1
Proflavine
1
Polymerase Chain Reaction
1
Paclitaxel
1
PM 01183
1
Methods
1
Metformin
1
Megestrol Acetate
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Interviews as Topic
1
Gene Expression Profiling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Endometrial Neoplasms
×
dostarlimab
×
Clear all
NCT06385548
2025-04-01
LiDer
Vall d'Hebron Institute of Oncology
Phase 1/2
Withdrawn